Danish pharma company Novo Nordisk has agreed to acquire Dicerna Pharmaceuticals and its ribonucleic acid interference (RNAi) platform in a deal valued at $3.3bn, to expand the RNAi technology use.
Pfizer has completed the acquisition of all outstanding shares of clinical-stage immuno-oncology firm Trillium Therapeutics in a deal worth about $2.22bn, or $18.50 per share, in cash.
Acelyrin has raised $250m through the series B financing round to license and acquire other programmes with focus on immunology.
AbbVie has extended a collaboration agreement with the University of Chicago until 2025 to support preclinical research in oncology.
Biotechnology firm Regenxbio and AbbVie have closed the previously announced license and collaboration deal for the development and commercialisation of the former’s gene therapy, RGX-314.
Merck has received antitrust clearance from the competition authorities in Germany and Austria to tender offer for the acquisition of clinical-stage biopharmaceutical firm Acceleron Pharma.
Dunad Therapeutics and Novartis have signed a strategic collaboration and license agreement to develop next generation targeted protein degrader therapies.
Synthekine and Merck have signed a global research collaboration and license agreement to develop novel cytokine-based therapeutics.
Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients with metastatic triple-negative breast cancer (TNBC).
Biotech company Immunai has raised $215m in Series B funding round to accelerate the development of its immune-first drug actuary platform.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.